Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice
DA Jabs, CL Burek, Q Hu, RC Kuppers, B Lee… - Cellular …, 1992 - Elsevier
Abstract MRL/Mp-lpr/lpr (MRL/lpr) mice spontaneously develop systemic autoimmune
disease, characterized by vasculitis, lymphadenopathy, glomerulonephritis, and
autoantibody formation. The target organ inflammatory lesions are composed largely of
CD4+“helper” T cells, while the massively enlarged lymph nodes are composed primarily of
CD3+ CD4− CD8− TCR α β+“double-negative” T cells. In this study we investigated the
effect of treatment of MRL/lpr mice with antiCD4 monoclonal antibody (mAb); control groups …
disease, characterized by vasculitis, lymphadenopathy, glomerulonephritis, and
autoantibody formation. The target organ inflammatory lesions are composed largely of
CD4+“helper” T cells, while the massively enlarged lymph nodes are composed primarily of
CD3+ CD4− CD8− TCR α β+“double-negative” T cells. In this study we investigated the
effect of treatment of MRL/lpr mice with antiCD4 monoclonal antibody (mAb); control groups …